Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
35 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsNeurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
(WorldNews Canada)

 
 

2 december 2019 14:46:49

 
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
(WorldNews Canada)
 


Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of EpilepsyXenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments Across All Licensed Products, as well as Option to Co-Fund XEN901 SAN DIEGO and BURNABY, British Columbia, Dec. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced a license and collaboration agreement to develop first-in-class treatments for epilepsy. Neurocrine Biosciences gains an exclusive license to XEN901, a clinical stage selective Nav1.6...


 
9 viewsCategory: General > North America > Canada
 
Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update on License and Collaboration Agreement with Neurocrine Biosciences
(WorldNews Canada)
Trevali Announces Drill Results For the Newly Discovered T3 Horizon at the Perkoa Mine and Updates on Regional Exploration and the Hanging Wall Lens Infill Programs
(WorldNews Canada)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten